ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

• Sponsor: Milestone Pharmaceuticals Inc. (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT04467905
• Collaborator: The Montreal Health Innovations Coordinating Center (MHICC) (Other), JSS Medical Research Inc. (Industry)
• Enrollment: 80
• Locations: 19
• Arms: 2
• Anticipated Duration (Months): 37.4
• Patients Per Site: 4.2
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

Many patients with atrial fibrillation experience persistent tachycardia with episodes of rapid ventricular rate despite chronic treatment to reduce ventricular rate. The objectives of this study are to demonstrate the superiority of a nasal spray of etripamil over placebo, in reducing ventricular rate in patients with atrial fibrillation; and to evaluate the safety and efficacy of etripamil Nasal Spray in patients with atrial fibrillation (AF).

Condition or Disease	Intervention/Treatment	Phase
Atrial Fibrillation	Drug: Etripamil; Drug: Placebo	Phase 2

Detailed Description

This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of etripamil Nasal Spray in patients with atrial fibrillation (AF). This study includes Screening, the Treatment Period and Follow-up procedures.

Each patient will receive placebo or 70 mg of etripamil intranasally; treatment will be randomized in a 1:1 ratio, to yield 50 evaluable patients with atrial fibrillation in 2 groups of 25.

Patients with atrial fibrillation (AF) will be selected by the Investigator. The screening procedures will include obtaining informed consent, a review of inclusion/exclusion criteria, a complete physical examination, and recording of any concomitant medications.

After screening procedures are complete, eligible patients will be randomized to receive etripamil or placebo. Heart rate will be measured via Holter ECG (Electrocardiogram)10 minutes prior to and immediately before drug administration; patients must exhibit a rapid ventricular rate (≥110 bpm measured during 1 minute) on the Holter report prior to drug administration in order to receive the study drug. Blinded study drug will be administered during Holter ECG (Electrocardiogram) monitoring, which will be conducted for at least 10 minutes prior to and for 6 hours after administration.

Patients will undergo a safety follow-up assessment and return the Holter device approximately 24 hours post-dose. Patients will also be contacted by phone 7 days post-dosing for safety follow-up.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 80 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Multi-Centre, Placebo-Controlled, Phase 2 Study of Etripamil Nasal Spray (NS) for the Reduction of Ventricular Rate in Patients With Atrial Fibrillation.
• Actual Study Start Date: Nov 19, 2020
• Anticipated Primary Completion Date: Dec 1, 2023
• Anticipated Study Completion Date: Jan 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Placebo Comparator: Placebo Patients will receive a total of 200 μL of placebo ((i.e. 100 μL in each nostril) via the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged. Instructions on device usage will be provided.	Drug: Placebo; The formulation of placebo will consist of water, sodium acetate, disodium, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid to reproduce the same pH as the etripamil formulation.
Experimental: Etripamil Patients will receive a total of 200 μL of etripamil Nasal spray 70 mg via the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged. Instructions on device usage will be provided.	Drug: Etripamil; The formulation of etripamil Nasal Spray will consist of MSP-2017 (etripamil), water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg.

Outcome Measures

Primary Outcome Measures

1. The maximum reduction in ventricular rate, measured on Holter monitoring, within 60 minutes from drug administration. [60 minutes post drug administration]

Secondary Outcome Measures

1. The elapsed time from drug administration to nadir (lowest average heart rate) in the 60 minutes post drug administration. [60 minutes post drug administration]

2. The percentage of patients achieving ventricular rate of <100 bpm in the 60 minutes post drug administration. [60 minutes post drug administration]

3. The percentage of patients with 10% reduction from baseline ventricular rate in the 60 minutes post drug administration. [60 minutes post drug administration]

4. The percentage of patients with 20% reduction from baseline ventricular rate in the 60 minutes post drug administration. [60 minutes post drug administration]

5. The percentage of patients cardioverting into sinus rhythm in the 60 minutes post drug administration. [60 minutes post drug administration]

6. Rating of Treatment Satisfaction Questionnaire for Medication (TSQM). [60 minutes post drug administration]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

A patient will be eligible for study participation if they meet all of the following criteria:

1. Aged 18 years and over.

2. Has provided written informed consent.

3. Patients with episodes of paroxysmal, persistent or permanent AF (Atrial Fibrillation), presenting with AF and a ventricular rate ≥110 bpm, measured over 1 minute

4. Patients should receive appropriate antithrombotic therapy as per the applicable guidelines for atrial fibrillation management (e.g., Canadian Cardiovascular Society (CCS) guidelines / European Society of Cardiology (ESC) guidelines).

5. Etripamil (a calcium channel blocker) is intended for acute rate control only. If rhythm control is desired (outside of the present protocol), anticoagulation as per guidelines may start after the administration of study drug.

Exclusion Criteria:

A patient will be excluded from the study if they meet any of the following criteria:

1. Has evidence of atrial flutter (ECG) at presentation.

2. Has a history of stroke,Transient Ischemic Attack (TIA) or peripheral embolism within the last 3 months.

3. Has received by IV route any of the following within one hour before study drug administration: flecainide, procainamide, digoxin, beta-blocker, or calcium channel blocker.

4. Has signs and symptoms of severe congestive heart failure at presentation (e.g. tachypnea, oxygen desaturation <90% unless due to known pulmonary disease, pulmonary rales, sign of peripheral hypoperfusion).

5. Hemodynamic instability, with systolic blood pressure <90 mmHg or diastolic blood pressure <60 mmHg.

6. Known uncorrected severe aortic or mitral stenosis.

7. Hypertrophic cardiomyopathy with outflow tract obstruction.

8. Has a history of second- or third-degree atrioventricular block.

9. Regular rhythm suggesting a complete Atrioventricular (AV) block.

10. Has a history or evidence of torsades de pointes, sick sinus syndrome, or Brugada syndrome.

11. Evidence of Acute Coronary Syndrome within the last 12 months except if patient was successfully revascularized.

12. Positive pregnancy test result at screening, and females of childbearing potential who do not agree to use adequate method of contraception for the duration of the study.

13. Has evidence of any clinically significant acute or chronic condition of the nasal cavity (e.g., rhinitis or deviated septum) which could interfere with administration of the study drug in either or both nasal cavities.

14. Has a history of sensitivity to verapamil.

15. Has previously participated in a clinical study for etripamil.

16. Has a history of sensitivity to any components of the investigational product.

17. Signs of alcohol or drug intoxication at the time of presentation which, in the opinion of the Investigator, would impact the validity of study results.

18. Is currently participating in another drug or device study, or has received an investigational drug or device within 30 days of Screening.

19. Has evidence of clinically significant cardiovascular, endocrine, gastrointestinal, hematologic, hepatic, immunologic, neurologic, oncologic, pulmonary, psychiatric, or renal disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the patient or impact the validity of study results.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	QEII HSC - Nova Scotia Health Authority	Halifax	Nova Scotia	Canada	B3H 3A7
2	Hamilton Health Science	Hamilton	Ontario	Canada	L2L 2X2
3	PACE (Partners in Advanced Cardiac Evaluation)	Newmarket	Ontario	Canada	L3Y 2P6
4	Ottawa Hospital General & Civic Campus Research Institute	Ottawa	Ontario	Canada	K1Y4E9
5	CIUSSS de l'Estrie-Centre Haute-Yamaska - Hôpital de Granby	Granby	Quebec	Canada	J2G 1T7
6	Institut de Cardiologie de Montreal	Montréal	Quebec	Canada	H1T 1C8
7	CHU Montréal	Montréal	Quebec	Canada	H2X 0A9
8	CIUSSS du Nord-de-l'Île-de-Montréal - Hôpital du Sacré-Cœur	Montréal	Quebec	Canada	H4J 1C5
9	CISSS Bas-Saint-Laurent / Hôpital de Rimouski	Rimouski	Quebec	Canada	G5L 5T1
10	CISSS des Laurentides / Unité de recherche clinique	Saint-Jérôme	Quebec	Canada	J7Z 5T3
11	CIUSSS de l'Estrie - CHU	Sherbrooke	Quebec	Canada	J1H 5N4
12	CISSS de Lanaudière - Hôpital Pierre-Le Gardeur	Terrebonne	Quebec	Canada	J6V 2H2
13	Jeroen Bosch Ziekenhuis Rijnstate Ziekenhuis	Arnhem		Netherlands	6815 AD
14	Jeroen Bosch Ziekenhuis	Den Bosch		Netherlands	5223 GZ
15	Slingeland Ziekenhuis	Doetinchem		Netherlands	7009 BL
16	Treant Zorggroep	Emmen		Netherlands	7824 AA
17	Elkerliek Ziekenhuis	Helmond		Netherlands	5707 HA
18	Franciscus Gasthuis	Rotterdam		Netherlands	3045 PM
19	Gelre Ziekenhuizen	Zutphen		Netherlands	7207 AE

Sponsors and Collaborators

• Milestone Pharmaceuticals Inc.
• The Montreal Health Innovations Coordinating Center (MHICC)
• JSS Medical Research Inc.

Investigators

• Principal Investigator: Denis Roy, M.D, Montreal Heart Institute (MHI)

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Milestone Pharmaceuticals Inc.
• ClinicalTrials.gov Identifier: NCT04467905
• Other Study ID Numbers: MSP-2017-5001
• First Posted: Jul 13, 2020
• Last Update Posted: Aug 5, 2022
• Last Verified: Aug 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: Yes
• Keywords provided by Milestone Pharmaceuticals Inc.: atrial fibrillation; ventricular rate control; rapid ventricular rate; etripamil
• Additional relevant MeSH terms: Atrial Fibrillation; Etripamil

Study Results

No Results Posted as of Aug 5, 2022